Ilyang Pharmaceutical’s ‘Supect’ effectively inhibits Parkinson’s disease progress

The preclinical and efficacy result on the Ilyang Pharmaceutical’s(President Dong-Yeon Kim) chronic myelocytic leukemia treatment ‘Supect(generic name: radotinib)’ for Parkinson’s disease(PD) was announced at the ‘American Academy of Neurology(AAM)’ symposium in Washington, D.C. on the 13^th of November(local time).

At the symposium, it was announced Supect has reportedly shown an effect of eff...